search
Back to results

BIOTRONIK Conduction System Pacing With the Solia Lead (BIO-CONDUCT)

Primary Purpose

Bradycardia, Atrioventricular Block, Left Bundle-Branch Block

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Solia S lead
Sponsored by
Biotronik, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bradycardia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is a candidate for implantation of a BIOTRONIK pacemaker system, per standard guidelines. Single chamber, dual chamber, and CRT-P systems are allowed.
  • Patient has an implant planned to utilize left bundle branch area pacing within 30 days of consent
  • Patient is able to understand the nature of the study and provide written informed consent
  • Patient is available for follow-up visits on a regular basis for the expected duration of follow-up
  • Patient accepts Home Monitoring® concept
  • Patient age is greater than or equal to 18 years at time of consent

Exclusion Criteria:

  • Patient meets a standard contraindication for pacemaker system implant
  • Patient is currently implanted with a pacemaker or ICD device
  • Patient has had a previous unsuccessful attempt to place a lead in the LBB area
  • Patient has planned cardiac surgical procedures or interventional measures within 3 months after implant
  • Patient is expected to receive a heart transplant within 12 months
  • Patient life expectancy less than 12 months
  • Patient has the presence of another life-threatening, underlying illness separate from their cardiac disorder
  • Patient reports pregnancy at the time of enrollment
  • Patient is enrolled in any other investigational cardiac clinical study during the course of the study

Sites / Locations

  • Banner - University Medical Center Phoenix
  • Sutter Medical Center Sacramento
  • Cardiology Associates Medical Group
  • Washington Hospital Center
  • Sarasota Memorial Health Care System
  • Tampa General Hospital
  • Rush University Medical Center
  • University of Chicago
  • Cardiology Associates
  • NYU Langone Health
  • Weill Cornell Medicine
  • Wake Forest University Health Sciences
  • Cardiology Consultants of Philadelphia
  • Geisinger
  • Medical University of South Carolina (MUSC)

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Solia S LBB lead

Arm Description

Outcomes

Primary Outcome Measures

Serious adverse device effect (SADE)-free rate at 3 months
Serious adverse device effect includes both serious lead related and serious implant related device effects. The overall percentage of subjects without serious lead related adverse device effects related to Solia S lead utilized or attempted to be implanted in the LBB area and serious implant procedure events related to the Solia S LBB lead will be reported.
Implant Success rate of the Solia S lead in LBB area
The overall percentage of subjects with successful placement of Solia S lead in LBB area.

Secondary Outcome Measures

Quality of Life (QOL) from baseline through 12 Months Post-Implant
This secondary outcome will evaluate the improvement in QOL for subjects with the Solia S lead implanted in the left bundle branch (LBB) area. The parameter of interest is the change in the physical function SF-36 (36-Item Short Form Health Survey) QOL scale from pre-implant baseline to 12 months post-implant, which will be calculated as the mean change from baseline for all subjects that complete both the baseline QOL and 12-month QOL questionnaire. Note that all items are scored so that a high score defines a more favorable health state. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.
Serious adverse device effect (SADE)-free rate at 6 months
Serious adverse device effect includes both serious lead related and serious implant related device effects. The overall percentage of subjects without serious lead related adverse device effects related to Solia S lead utilized or attempted to be implanted in the LBB area and serious implant procedure events related to the Solia S LBB lead will be reported.
Serious adverse device effect (SADE)-free rate at 12 months
Serious adverse device effect includes both serious lead related and serious implant related device effects. The overall percentage of subjects without serious lead related adverse device effects related to Solia S lead utilized or attempted to be implanted in the LBB area and serious implant procedure events related to the Solia S LBB lead will be reported.
Pacing threshold measurements for Solia S lead at 3 months
Pacing threshold measurements for Solia S leads implanted in the LBB area at the 3 month follow-up visit.
Sensing measurements for Solia S lead at 3 months
R-wave sensing amplitude measurements for Solia S leads implanted in the LBB area at the 3 month follow-up visit.
Pacing impedance for Solia S lead at 3 months
Pacing impedance measurements for Solia S leads implanted in the LBB area at the 3 month follow-up visit.
Pacing threshold measurements for Solia S lead at 6 months
Pacing threshold measurements for Solia S leads implanted in the LBB area at the 6 month follow-up visit.
Sensing measurements for Solia S lead at 6 months
R-wave sensing amplitude measurements for Solia S leads implanted in the LBB area at the 6 month follow-up visit.
Pacing impedance for Solia S lead at 6 months
Pacing impedance measurements for Solia S leads implanted in the LBB area at the 6 month follow-up visit.
Pacing threshold measurements for Solia S lead at 12 months
Pacing threshold measurements for Solia S leads implanted in the LBB area at the 12 month follow-up visit.
Sensing measurements for Solia S lead at 12 months
R-wave sensing amplitude measurements for Solia S leads implanted in the LBB area at the 12 month follow-up visit.
Pacing impedance for Solia S lead at 12 months
Pacing impedance measurements for Solia S leads implanted in the LBB area at the 12 month follow-up visit.

Full Information

First Posted
February 7, 2022
Last Updated
October 20, 2023
Sponsor
Biotronik, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05251363
Brief Title
BIOTRONIK Conduction System Pacing With the Solia Lead
Acronym
BIO-CONDUCT
Official Title
BIOTRONIK Conduction System Pacing With the Solia Lead
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 12, 2022 (Actual)
Primary Completion Date
February 1, 2024 (Anticipated)
Study Completion Date
November 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Biotronik, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the BIO-CONDUCT study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area. Safety will be assessed by evaluating serious adverse device effects that occur through 3 months post-implant. Efficacy will be assessed by evaluating implant success rate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bradycardia, Atrioventricular Block, Left Bundle-Branch Block, Cardiomyopathies

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
186 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Solia S LBB lead
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
Solia S lead
Intervention Description
The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
Primary Outcome Measure Information:
Title
Serious adverse device effect (SADE)-free rate at 3 months
Description
Serious adverse device effect includes both serious lead related and serious implant related device effects. The overall percentage of subjects without serious lead related adverse device effects related to Solia S lead utilized or attempted to be implanted in the LBB area and serious implant procedure events related to the Solia S LBB lead will be reported.
Time Frame
3 months post implant
Title
Implant Success rate of the Solia S lead in LBB area
Description
The overall percentage of subjects with successful placement of Solia S lead in LBB area.
Time Frame
at implant procedure
Secondary Outcome Measure Information:
Title
Quality of Life (QOL) from baseline through 12 Months Post-Implant
Description
This secondary outcome will evaluate the improvement in QOL for subjects with the Solia S lead implanted in the left bundle branch (LBB) area. The parameter of interest is the change in the physical function SF-36 (36-Item Short Form Health Survey) QOL scale from pre-implant baseline to 12 months post-implant, which will be calculated as the mean change from baseline for all subjects that complete both the baseline QOL and 12-month QOL questionnaire. Note that all items are scored so that a high score defines a more favorable health state. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.
Time Frame
12 months post implant
Title
Serious adverse device effect (SADE)-free rate at 6 months
Description
Serious adverse device effect includes both serious lead related and serious implant related device effects. The overall percentage of subjects without serious lead related adverse device effects related to Solia S lead utilized or attempted to be implanted in the LBB area and serious implant procedure events related to the Solia S LBB lead will be reported.
Time Frame
6 months post implant
Title
Serious adverse device effect (SADE)-free rate at 12 months
Description
Serious adverse device effect includes both serious lead related and serious implant related device effects. The overall percentage of subjects without serious lead related adverse device effects related to Solia S lead utilized or attempted to be implanted in the LBB area and serious implant procedure events related to the Solia S LBB lead will be reported.
Time Frame
12 months post implant
Title
Pacing threshold measurements for Solia S lead at 3 months
Description
Pacing threshold measurements for Solia S leads implanted in the LBB area at the 3 month follow-up visit.
Time Frame
3 months post implant
Title
Sensing measurements for Solia S lead at 3 months
Description
R-wave sensing amplitude measurements for Solia S leads implanted in the LBB area at the 3 month follow-up visit.
Time Frame
3 months post implant
Title
Pacing impedance for Solia S lead at 3 months
Description
Pacing impedance measurements for Solia S leads implanted in the LBB area at the 3 month follow-up visit.
Time Frame
3 months post implant
Title
Pacing threshold measurements for Solia S lead at 6 months
Description
Pacing threshold measurements for Solia S leads implanted in the LBB area at the 6 month follow-up visit.
Time Frame
6 months post implant
Title
Sensing measurements for Solia S lead at 6 months
Description
R-wave sensing amplitude measurements for Solia S leads implanted in the LBB area at the 6 month follow-up visit.
Time Frame
6 months post implant
Title
Pacing impedance for Solia S lead at 6 months
Description
Pacing impedance measurements for Solia S leads implanted in the LBB area at the 6 month follow-up visit.
Time Frame
6 months post implant
Title
Pacing threshold measurements for Solia S lead at 12 months
Description
Pacing threshold measurements for Solia S leads implanted in the LBB area at the 12 month follow-up visit.
Time Frame
12 months post implant
Title
Sensing measurements for Solia S lead at 12 months
Description
R-wave sensing amplitude measurements for Solia S leads implanted in the LBB area at the 12 month follow-up visit.
Time Frame
12 months post implant
Title
Pacing impedance for Solia S lead at 12 months
Description
Pacing impedance measurements for Solia S leads implanted in the LBB area at the 12 month follow-up visit.
Time Frame
12 months post implant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is a candidate for implantation of a BIOTRONIK pacemaker system, per standard guidelines. Single chamber, dual chamber, and CRT-P systems are allowed. Patient has an implant planned to utilize left bundle branch area pacing within 30 days of consent Patient is able to understand the nature of the study and provide written informed consent Patient is available for follow-up visits on a regular basis for the expected duration of follow-up Patient accepts Home Monitoring® concept Patient age is greater than or equal to 18 years at time of consent Exclusion Criteria: Patient meets a standard contraindication for pacemaker system implant Patient is currently implanted with a pacemaker or ICD device Patient has had a previous unsuccessful attempt to place a lead in the LBB area Patient has planned cardiac surgical procedures or interventional measures within 3 months after implant Patient is expected to receive a heart transplant within 12 months Patient life expectancy less than 12 months Patient has the presence of another life-threatening, underlying illness separate from their cardiac disorder Patient reports pregnancy at the time of enrollment Patient is enrolled in any other investigational cardiac clinical study during the course of the study
Facility Information:
Facility Name
Banner - University Medical Center Phoenix
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
Sutter Medical Center Sacramento
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
Cardiology Associates Medical Group
City
Ventura
State/Province
California
ZIP/Postal Code
93003
Country
United States
Facility Name
Washington Hospital Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20010
Country
United States
Facility Name
Sarasota Memorial Health Care System
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34239
Country
United States
Facility Name
Tampa General Hospital
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Cardiology Associates
City
Tupelo
State/Province
Mississippi
ZIP/Postal Code
38801
Country
United States
Facility Name
NYU Langone Health
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Weill Cornell Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Wake Forest University Health Sciences
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
Cardiology Consultants of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Geisinger
City
Wilkes-Barre
State/Province
Pennsylvania
ZIP/Postal Code
18711
Country
United States
Facility Name
Medical University of South Carolina (MUSC)
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified participant level data collected within the study will be shared for approved requests.
IPD Sharing Time Frame
The data will be available beginning no later than 12 months and ending 3 years after study.
IPD Sharing Access Criteria
Proposals should be directed to BIOTRONIK Clinical Studies (BIOTRONIK Inc., Attn: Clinical Studies, 6024 Jean Road, Lake Oswego, OR; 1-800-547-0394). BIOTRONIK, in consultation with the National Principal Investigator, will review and critique requests for scientific merit, fiscal feasibility, and logistical feasibility. If approved, the data requestors will need to sign a data use/access agreement prior to obtaining the data. BIOTRONIK reserves the right to delete any confidential information or other proprietary information (including trade secrets and patent protected materials) from the shared information.

Learn more about this trial

BIOTRONIK Conduction System Pacing With the Solia Lead

We'll reach out to this number within 24 hrs